If approved, pemigatinib would be the first targeted therapy for patients with cholangiocarcinoma, a rare cancer that impacts the bile ducts. The disease is often diagnosed at a late or advanced stage.
Findings from a phase 2 study assessing pemigatinib in patients with previously treated, advanced cholangiocarcinoma are supporting Incyte’s planned submission for a New Drug Application for the selective fibroblast growth factor receptor (FGFR) inhibitor by the end of the year.
If approved, pemigatinib would be the first approved targeted therapy for patients with cholangiocarcinoma, a rare cancer that impacts the bile ducts. The disease is often diagnosed at a late or advanced stage.
“Patients with cholangiocarcinoma face a significant challenge as they cope with a life-threatening condition that is often diagnosed once it has progressed into late stages,” Arndt Vogel, MD, senior consultant and professor at Hannover Medical School, said in a statement. “As a physician, I am encouraged to see the data from the FIGHT-202 study, which demonstrate the potential that pemigatinib has to become an important and much needed target option for this patient population.”
Findings from the FIGHT-202 study, presented at the European Society of Medical Oncology 2019 Congress in Barcelona, Spain, showed that pemigatinib resulted in an overall response rate of 36% and median progression-free survival of 6.9 months following a median of 15 months of follow-up in patients with FGFR2 fusions or rearrangements.
The study included 3 cohorts: those with FGFR2 fusions or rearrangements, those with other FGF/FGFR genetic alterations, and those with no FGF/FGFR genetic alterations. All patients received 13.5 mg pemigatinib orally once daily on a 21-day cycle until disease progression or until unacceptable toxicity.
Three of the 107 patients with FGFR2 fusions or rearrangements achieved a complete response rate while 35 achieved a partial response. Among these patients, there was a disease control rate of 82% and the median duration of response was 7.5 months. Preliminary data on overall survival showed a median overall survival of 21.1 months.
“We are excited to share updated data for pemigatinib, which may provide a promising and targeted treatment approach for patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements,” said Peter Langmuir, MD, group vice president, targeted therapies, Incyte, in a statement. “Patients with advanced cholangiocarcinoma face a poor prognosis, and currently there is no standard of care beyond first-line chemotherapy.”
The safety analysis of 146 patients indicated that pemigatinib was generally well tolerated, with the most common treatment-emergent adverse event being grade 1 or 2 hyperphosphatemia. This adverse event was managed with a low phosphate diet, phosphate binders and diuretics, or dose reduction or interruption.
The most common grade 3 or higher treatment-emergent adverse event was hypophosphatemia (12%); however, none of the cases were considered clinically significant or serious and none resulted in a dose reduction or discontinuation.
In June, Incyte announced that the first patient had been treated in a phase 3 trial comparing pemigatinib with gemcitabine with cisplatin chemotherapy as first-line therapy for the diesase.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More